Skip Navigation Bar
National Library of Medicine Technical BulletinNational Library of Medicine Technical Bulletin

Table of Contents: 2022 JULY–AUGUST No. 447

Previous Next

RxNorm July 2022 Release

RxNorm July 2022 Release. NLM Tech Bull. 2022 Jul-Aug;(447):b2.

2022 July 05 [posted]

The RxNorm July 2022 monthly release became available on Tuesday, July 5, 2022, and includes a new dose form "Drug-Eluting Contact Lens" and a new concept for Lagevrio, which is a brand name COVID-19 medication.

RxNorm Data Changes

New Dose Form

RxNorm includes a new dose form: Drug-Eluting Contact Lens. This dose form is defined as a contact lens intended for use in the eye that releases a medication.

Here are the fully specified product name concepts with the new dose form "Drug-Eluting Contact Lens" in the July 2022 release:

2604045 SCD ketotifen 0.019 MG Drug-Eluting Contact Lens
2604049 SBD ketotifen 0.019 MG Drug-Eluting Contact Lens [Acuvue Theravision]

Lagevrio COVID-19 Medication Concept Added

The molnupiravir COVID-19 medication will be available under the brand name Lagevrio. To reflect this change, a Semantic Branded Drug (SBD) concept for Lagevrio is included in the RxNorm July monthly release. The National Drug Codes (NDCs) for Lagevrio were previously associated with the generic molnupiravir drug concept. NDCs moved from RXCUI 2587906 to RXCUI 2603740. Get more information about Lagevrio from the U.S. Food and Drug Administration (FDA).

Here is the new Lagevrio COVID-19 medication concept in RxNorm:

2603740 SBD molnupiravir 200 MG Oral Capsule [Lagevrio]


NLM Technical Bulletin National Library of Medicine National Institutes of Health